{"preliminary_commentary":{"by_channel":{"x_thread":6,"youtube":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04876651\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-16T20:51:07.200Z","note":"Automated from all 9 indexed sources (Jan 2022 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":9,"text":"- Whether adding 177Lu-rosopatamab to an ARPI or docetaxel improves on that standard of care alone\n- Whether 177Lu-rosopatamab in ProstACT offers more than 177Lu-PSMA-617, and how the two would be sequenced\n- Whether 177Lu-rosopatamab spares salivary glands and kidneys, and what its liver uptake means for safety","kind":"questions"},"drugs_tested":null,"indication":"PSMA-expressing metastatic castration-resistant prostate cancer","name":"NCT04876651","nct_id":"NCT04876651","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04876651. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care","label":"Group A","type":"EXPERIMENTAL"},{"description":"Participants will receive the Standard of Care","label":"Group B","type":"ACTIVE_COMPARATOR"},{"description":"Two single intravenous (IV) injections of 76 mCi each (equivalent to a 45 mCi/m2 dose in a standard 1.7m2 individual) of 177Lu-DOTA- rosopatamab, given 14 days apart, plus best Standard of Care","label":"Biodistribution and Dosimetry Sub-Study","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-07-01","type":"ACTUAL"},"conditions":["Metastatic Prostate Cancer"],"enrollment":{"count":16,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"177Lu-DOTA-rosopatamb","otherNames":["177Lu-TLX591"],"type":"OTHER"},{"name":"Standard of Care","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-20","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","official_title":"A Multinational, Multicenter, Prospective, Randomized, Controlled, Open Label Phase 3 Study With Best Standard of Care With and Without 177Lu-DOTA-rosopatamab for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment With a Novel Androgen Axis Drug","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Comparison of radiographic progression-free survival (rPFS)","timeFrame":"Day 1 to 5 years after two administrations of 177Lu-DOTA-rosopatamab"}],"references":[],"start_date":{"date":"2023-08-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","url":"https://clinicaltrials.gov/study/NCT04876651"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04876651"}